2025 China National Reimbursement Drug List Released: Multiple Blockbusters Miss Out, Five CAR-T Therapies Enter Commercial Insurance, Hengrui Emerges as Top Winner
Fosun Pharmaceutical
Healthcare Industry Group
Juventas
Innovative Cell Therapy Drug Developer
IASO Biotechnology
Cancer Treatment New Drug Developer
On December 7, the National Medical Products Administration announced the adjustment results of the 2025 medical insurance directory, marking the 8th adjustment since the establishment of the National Healthcare Security Administration. A total of 114 drugs were newly added this time, including 50 Class 1 innovative drugs and 7 traditional Chinese medicine varieties, with an overall success rate of 88%, significantly higher than the 76% in 2024. Additionally, 29 drugs that have been clinically replaced or have not been produced or supplied for a long time were removed. The new directory will be implemented nationwide in China starting from January 1, 2026.
After this adjustment, the total number of drugs in the basic medical insurance catalog has reached 3,253. For negotiated drugs within the agreement period that were not successfully renewed and have been removed from the catalog in this adjustment, a six-month transition period will be granted to ensure continuity of medication use.
MaxEntropy Pharma Database has been updated with the 2025 National Reimbursement Drug List, including detailed data on drug classification and additions. Available atMaxEntropy Pharma - Market Access - National Reimbursement Drug List (NRDL)View, to provide support for industry research decisions.
To apply for a database trial, scan the QR code below.
19 varieties included in the commercial insurance catalog, including 5 CAR-T drugs
【Official Website Version】2025 National Medical Insurance Catalog: 114 Newly Added Products and Enterprises List (Including 19 Commercial Insurance Catalog Items)The much-anticipated first edition of the Commercial Insurance Innovative Drug List includes 19 drugs, including CAR-T and other cancer treatments, drugs for rare diseases such as neuroblastoma and Gaucher's disease, as well as treatments for Alzheimer's disease.
Source of Screenshot:Detailed data can be viewed at Mosan Pharmaceuticals - Market Access - Medical Insurance Catalog.
High-priced drugs have always been the focus of adjustments to the medical insurance catalog. Previously, CAR-T therapy costing millions per dose was out of reach for ordinary patients due to its high cost. This time, there is a turning point in the medical insurance adjustment, with five CAR-T drugs passing the preliminary review and entering the commercial insurance innovative drug directory, breaking the deadlock in the high-priced drug market.
Among them, Fosun Pharmaceutical priced at 1.2 million RMB/bagAxicabtagene Ciloleucel, which has been applied for inclusion in the national medical insurance catalog for four consecutive years. It passed the formal review in both 2021 and 2023 but ultimately failed to enter the catalog. However,Axicabtagene CiloleucelIt has built a broad commercial insurance network, being included in over 80 commercial medical insurance plans and more than 80 city-level "People's Benefit Insurance" programs, accumulating experience for its inclusion in the national commercial insurance innovative drug directory.
JuventasTheNaciorl, was approved for marketing in 2023 and is currently the only domestically produced product in China that covers both leukemia and lymphoma, two major hematological malignancies.CAR-TAt the beginning of last month, during the on-site negotiations for the National Medical Insurance Directory and the price consultation for the Commercial Insurance Innovative Drug Directory, the negotiation for this particular drug was very successful. It became the first to make progress through the commercial insurance pathway.CAR-TProduct.
Source of Screenshot:MaxEntropy Pharma Global Drug R&D Database
IASO BioTheEquecabtagene Autoleucel、KaiXing LifeTheZevorcleucelBoth are fully human anti-BCMA CAR-T therapies, used for the treatment of myeloma;JW TherapeuticsTheRelma-celIt is the only CAR-T in China approved for three non-Hodgkin lymphoma indications, with all three costing over a million RMB per injection.
In addition,EisaiTheLecanemab、Eli LillyTwo new AD drugs, Donanemab andCANbridgeTreatment for Gaucher's DiseaseVelaglucerase β for Injection、TakedaTreatment for Short Bowel SyndromeTeduglutide for InjectionSeveral rare disease drugs have been included in the commercial insurance innovative drug directory.
Multiple GLP-1 drugs enter medical insurance, weight loss effects not included
Apart from high-priced drugs, GLP-1 related drugs have achieved a significant breakthrough in this year's medical insurance catalog. The newly crowned "global top-selling drug"Eli LillyTheTirzepatide InjectionEntered the medical insurance directory for the first time, used for adult Type 2 diabetes treatment, with global sales exceeding $11.5 billion in 2024. In addition,Novo NordiskTheSemaglutideInclusion in medical insurance upon reapplication after protocol expiration.
Screenshot source:MaxEntropy Pharma Global Drug R&D Database
Multiple GLP-1 drugs produced in China have also been included.Hansoh PharmaThePolyethylene Glycol LoosenatideIt is the first domestically produced long-acting GLP-1 preparation with independent intellectual property rights in China, utilizing pegylation technology to extend its duration of action, requiring only one injection per week.Yinuo PharmaceuticalTheEsupaglutide αIt is a long-acting GLP-1 receptor agonist with a half-life of up to 204 hours, approved earlier this year. However, the current indications for GLP-1 drugs in the directory are all for diabetes, and the weight loss effect has not been included in this directory.
Hengrui Pharma Emerges as the Biggest Winner, Multiple Pharma Companies Reap Rich Harvests
In the 2025 medical insurance negotiations, Chinese pharmaceutical companies performed remarkably.Hengrui MedicineThe biggest winner, with 20 products/indications completing adjustments, 10 new drugs entering the catalog for the first time, 5 with newly added indications, 5 successfully renewed, and 14 of 16 marketed innovative drugs included in the medical insurance.
BeiGeneMultiple products and newly added indications covered by medical insurance and commercial insurance;Fosun PharmaceuticalFive drugs have been included in the medical insurance for the first time;Akeso BiopharmaFive self-developed new drugs approved for indications have been fully included in medical insurance.Innovent Biologics7 New Drugs Added to the Updated Directory; Currently, This Pharmaceutical Company Has 17 New Drugs Approved, with All 12 Innovative Drugs Included in the National Medical Insurance.
Source of Screenshot:MaxEntropy Pharma Global Drug R&D Database
Junshi BiosciencesTheToripalimabAdd 2 Indications,OngoriximabFirst entry;Zhongsheng PharmaceuticalA New Class of DrugsAnglade TabletsFirst inclusion in medical insurance, multiple core productsVarietyRenewal.CelonTwo types of powder-liquid dual-chamber bags,Zelgen BiologicsTheGicarceptib Hydrochloride TabletsWait for the first entry into the directory. In addition,Huadong Medicine3 ProductsInclusion or Adjustment of Directory，Xingqi Eye DropsThere are 39 renewable insurance policies.Edding PharmaTwo New Breast Cancer Drugs Enter医保 for the First Time, One Shifts to Routine Use, Highlighting Innovation and Clinical Value.
This achievement is overall fruitful, but there are still highly anticipated varieties that did not make it into the medical insurance or commercial insurance catalogs. For example,EisaiTheLemborexant Tablets、Simcere PharmaceuticalTheDaridorexant HydrochlorideAlthough passed the formal review of the 2025 National Medical Insurance and Commercial Insurance Innovative Drug List, it did not make it into the final basic medical insurance or the first edition of the commercial insurance innovative drug list.
The number of drugs in China's national medical insurance catalog has increased to 3,253. For innovative drugs successfully included in the catalog, the transition from "astronomical prices" to "affordable costs" has been achieved through a "volume-for-price" strategy. Five CAR-T therapies and multiple drugs for Alzheimer's disease (AD) and rare diseases have entered commercial insurance, breaking the deadlock for high-cost drugs while also broadening the coverage for medications treating special diseases. Despite the overall fruitful results this time, some highly anticipated drug varieties did not make the cut, highlighting the strictness of the medical insurance adjustment process. In the future, continuous adjustments to medical insurance policies will further promote industry innovation and development, benefit people's livelihoods, and safeguard patients' health.
Attachment: 1. National Basic Medical Insurance, Maternity Insurance, and Work-related Injury Insurance Drug Catalog (2025)
2. Commercial Health Insurance Innovative Drug List (2025)
*To obtain related attachments, reply "2025 Medical Insurance" in the official account backend.
END
This article is original. Please leave a message to obtain authorization for reprint.
More RecentlyMoso ConsultancyPopular Report, Scan the QR Code Below to Claim
Contact us to experience more professional services from Mosen Pharmaceuticals. | ||||
WillDiscussion JuventasWork | GardenDistrict TakeMission | Database Consultation | Customization Service | Media Cooperation |
ClickImage Above, you can start the Mosan Chemistry data query
